{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:35:03Z","timestamp":1792859703690,"version":"4.5.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>In a hepatitis C virus (HCV)\/HIV-positive Brazilian cohort, evaluate the safety and efficacy of HCV DAAs, the frequency of resistance substitutions in the HCV NS5A and NS5B genes and identify predictors of treatment failure.<\/jats:p>\n            <jats:p>Retrospective multicenter study of HCV\/HIV patients treated with sofosbuvir (SOF)-based regimens at 10 reference centers in Brazil.<\/jats:p>\n            <jats:p>Clinical and virological data were collected. Genetic diversity in the NS5A and NS5B genes was assessed by direct nucleotide sequencing. The primary outcome was sustained virological response (SVR) 12 weeks after DAA completion.<\/jats:p>\n            <jats:p>Of 643\u200aHCV\/HIV patients analyzed, 74.7% were male, median CD4+ T cell count was 617\u200acells\/mm<jats:sup>3<\/jats:sup>, 90% had an undetectable HIV viral load. HCV genotype 1 was detected in 80.2%, and 60% were taking at least 1 medication other than antiretroviral drugs during their DAA therapy. Cirrhosis was present in 42%. An SOF\/daclatasvir (DCV) regimen was used in most patients (98%). The frequency of NS5A polymorphisms associated with clinically relevant resistance to DCV was 2%; no relevant NS5B variants were identified. The SVR12 rate was 92.8% in an intention to treat (ITT) analysis and 96% in a modified ITT (m-ITT) analysis. AE occurred in 1.6% of patients. By multivariate analysis, therapeutic failure was associated, in the m-ITT analysis, with concomitant use of anticonvulsant drugs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001), age (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.04), and female gender (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.04).<\/jats:p>\n            <jats:p>SOF\/DCV regimens were associated with a high SVR rate in an HCV\/HIV population. The use of concurrent anticonvulsant drugs and DAAs decreases the chances of achieving an SVR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021270","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:06:26Z","timestamp":1595372786000},"page":"e21270","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C\/HIV coinfected individuals"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-3995","authenticated-orcid":false,"given":"Soraia M.","family":"Machado","sequence":"first","affiliation":[{"name":"University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline G.","family":"Vigani","sequence":"additional","affiliation":[{"name":"State University of Campinas, Campinas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Leite","sequence":"additional","affiliation":[{"name":"Center Specialized in Health, Caxias Do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia M.","family":"Diaz","sequence":"additional","affiliation":[{"name":"Infectious Disease Outpatient Clinic, Jundia\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Roberto A.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Federal University of S\u00e3o Paulo, Infectious Diseases Department, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Carna\u00faba-J\u00fanior","sequence":"additional","affiliation":[{"name":"Centro De Refer\u00eancia e Treinamento - CRT DST-AIDS, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone B.","family":"Tenore","sequence":"additional","affiliation":[{"name":"Centro De Refer\u00eancia e Treinamento - CRT DST-AIDS, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Brand\u00e3o-Mello","sequence":"additional","affiliation":[{"name":"Federal University of the State of Rio de Janeiro, Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario P.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Emilio Ribas Hospital, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Siroma","sequence":"additional","affiliation":[{"name":"Emilio Ribas Hospital, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleber D.","family":"Prado","sequence":"additional","affiliation":[{"name":"Heli\u00f3polis Hospital, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delzi V.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Base Hospital- Funfarme, S\u00e3o Jos\u00e9 Do Rio Preto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspar","family":"Lisboa-Neto","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Renato R.","family":"Pinho","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo"},{"name":"LIM 07, Institute of Tropical Medicine, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda M.","family":"Malta","sequence":"additional","affiliation":[{"name":"LIM 07, Institute of Tropical Medicine, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymundo S.","family":"Azevedo","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Witkin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY"},{"name":"LIM 52, Institute of Tropical Medicine, S\u00e3o Paulo."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C\u00e1ssia","family":"Mendes-Correa","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo"},{"name":"LIM 52, Institute of Tropical Medicine, S\u00e3o Paulo."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2017.03.012","article-title":"Economic burden of hepatitis C infection","volume":"21","author":"Stepanova","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"(1 suppl)","key":"R4-20230915","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection","volume":"44","author":"Alter","year":"2006","journal-title":"J Hepatol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/COH.0000000000000064","article-title":"Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play?","volume":"9","author":"Rockstroh","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/COH.0000000000000187","article-title":"Natural history of liver disease and affect of hepatitis C virus on HIV disease progression","volume":"10","author":"Ingiliz","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/cid\/ciw380","article-title":"Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus-coinfected individuals from 2001 to 2014: a multicohort study","volume":"63","author":"Gj\u00e6rde","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.02.004","article-title":"Towards hepatitis C eradication from the HIV-infected population","volume":"105","author":"Barreiro","year":"2014","journal-title":"Antiviral Res"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0034-1371012","article-title":"Interferon-containing and Interferon-free HCV Therapy for HIV-infected Patients","volume":"34","author":"Sulkowski","year":"2014","journal-title":"Semin Liver Dis"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/2047-783X-14-12-507","article-title":"The treatment of chronic hepatitis C virus infection in HIV co-infection","volume":"14","author":"Vogel","year":"2009","journal-title":"Eur J Med Res"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-6405-11-16","article-title":"German cohort of HCV mono-infected and HCV\/HIV co-infected patients reveals relative under-treatment of co-infected patients","volume":"11","author":"Beisel","year":"2014","journal-title":"AIDS Res Ther"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciw163","article-title":"12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens","volume":"62","author":"Luetkemeyer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R17-20230915","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx154","article-title":"Safety and efficacy of ombitasvir, paritaprevir with ritonavir \u00b1 dasabuvir with or without Ribavirin in patients with human immunodeficiency virus-1 and hepatitis c virus genotype 1 or genotype 4 coinfection: TURQUOISE-I Part 2","volume":"4","author":"Rockstroh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral direct-acting antiviral regimens in HIV\/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort","volume":"63","author":"Sogni","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/hiv.12579","article-title":"Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?","volume":"19","author":"Bischoff","year":"2018","journal-title":"HIV Med"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"Milazzo","year":"2017","journal-title":"HIV Med"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus\/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings","volume":"68","author":"Berenguer","year":"2018","journal-title":"Hepatology"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15284336.2017.1330801","article-title":"HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study","volume":"18","author":"Neukam","year":"2017","journal-title":"HIV Clin Trials"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3851\/IMP3061","article-title":"Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials","volume":"22","author":"Arias","year":"2017","journal-title":"Antivir Ther"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"ofx158","DOI":"10.1093\/ofid\/ofx158","article-title":"Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus\/human immunodeficiency virus coinfection","volume":"4","author":"Boesecke","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/QAD.0000000000001135","article-title":"Is HIV still a special population for the treatment of hepatitis C?","volume":"30","author":"Cachay","year":"2016","journal-title":"AIDS"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"ofx264","DOI":"10.1093\/ofid\/ofx264","article-title":"Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection","volume":"5","author":"Collins","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.29642","article-title":"Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population","volume":"67","author":"Sikavi","year":"2018","journal-title":"Hepatology"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11904-017-0369-5","article-title":"Resistance to DAAs: when to look and when it matters","volume":"14","author":"Wyles","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co-infection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0022-2836(75)90213-2","article-title":"A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase","volume":"94","author":"Sanger","year":"1975","journal-title":"J Mol Biol"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV]\u2014a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/QAD.0000000000001020","article-title":"Interferon-free treatment with sofosbuvir\/daclatasvir achieves sustained virologic response in 100% of HIV\/hepatitis C virus-coinfected patients with advanced liver disease","volume":"30","author":"Mandorfer","year":"2016","journal-title":"AIDS"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3851\/IMP3108","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease","volume":"22","author":"Rockstroh","year":"2017","journal-title":"Antivir Ther"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/QAI.0000000000001342","article-title":"Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV\/HCV coinfected patients with advanced liver disease in a French early access cohort","volume":"75","author":"Lacombe","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"R46-20230915","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3\u00fe)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"R47-20230915","first-page":"24","article-title":"Use of daclatasvir in HCV\/HIV-coinfected patients in a real-life setting","volume":"19","author":"Bonora","year":"2017","journal-title":"AIDS Rev"},{"key":"R48-20230915","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s12325-016-0407-5","article-title":"A review of daclatasvir drug\u2013drug interactions","volume":"33","author":"Garimella","year":"2016","journal-title":"Adv Ther"},{"key":"R49-20230915","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17512433.2018.1519392","article-title":"The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs","volume":"11","author":"Roncero","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R50-20230915","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/hiv.12570","article-title":"Management of drug interactions with direct-acting antivirals in Dutch HIV\/hepatitis C virus-coinfected patients: adequate but not perfect","volume":"19","author":"Smolders","year":"2018","journal-title":"HIV Med"},{"key":"R51-20230915","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R52-20230915","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3851\/IMP1935","article-title":"Pegylated interferon-\u03b12a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort","volume":"17","author":"Bourli\u00e8re","year":"2012","journal-title":"Antivir Ther"},{"issue":"(suppl 3)","key":"R53-20230915","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/01.aids.0000192077.11067.e5","article-title":"Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV\/HCV-co-infected veterans","volume":"19","author":"Goulet","year":"2005","journal-title":"AIDS"},{"key":"R54-20230915","doi-asserted-by":"crossref","first-page":"e0184654","DOI":"10.1371\/journal.pone.0184654","article-title":"Real-life results of sofosbuvir based therapy in chronic hepatitis C-na\u00efve and -experienced patients in Egypt","volume":"12","author":"Nagaty","year":"2017","journal-title":"PLoS One"},{"key":"R55-20230915","doi-asserted-by":"crossref","first-page":"e0199941","DOI":"10.1371\/journal.pone.0199941","article-title":"All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: the role of cirrhosis and comorbidities in treatment response","volume":"13","author":"Miotto","year":"2018","journal-title":"PLoS One"},{"key":"R56-20230915","article-title":"Predictors of Lack of Hepatitis C Eradication Using Direct-Acting Antivirals [Poster 609]","author":"Cachay","year":"2018","journal-title":"25th Conference on Retroviruses and opportunistic infections (CROI)"},{"key":"R57-20230915","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/YCO.0b013e32832cadb9","article-title":"Psychiatric and substance use disorders comorbidities in veterans with hepatitis C virus and HIV coinfection","volume":"22","author":"Fuller","year":"2009","journal-title":"Curr Opin Psychiatry"},{"key":"R58-20230915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J Clin Virol"},{"key":"R59-20230915","first-page":"203","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"R60-20230915","doi-asserted-by":"crossref","first-page":"308.e5","DOI":"10.1016\/j.cmi.2017.08.003","article-title":"Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy","volume":"24","author":"Caudai","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R61-20230915","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12879-017-2817-7","article-title":"Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil","volume":"17","author":"Malta","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R62-20230915","doi-asserted-by":"crossref","first-page":"e0216327","DOI":"10.1371\/journal.pone.0216327","article-title":"Treatment of chronic HCV infection with DAAs in Rio de Janeiro\/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes","volume":"14","author":"Costa","year":"2019","journal-title":"PLoS One"},{"key":"R63-20230915","doi-asserted-by":"crossref","first-page":"ofx264","DOI":"10.1093\/ofid\/ofx264","article-title":"Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection","volume":"5","author":"Collins","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:01:59Z","timestamp":1694826119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021270"}},"subtitle":["A multicenter study"],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":59,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021270","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}